Health care spending in the United States is increasing faster than the gross domestic product. This trend is obviously neither preferable nor sustainable. And all players are on board for solutions. All players also want a system in which consumers receive the best available options for care, one that prioritizes growth and innovation. Enter the
Details

The life science industry is on a never-ending quest to engage the right stakeholders. Most healthcare executives already realize the need for identifying and mapping clinical key opinion leaders (KOLs). Yet many miss that this is only a small piece of the integrated network that is critical to engage. In fact, extra value can come
Details

The world is becoming more connected and consumers now have virtually limitless access to medical information. Social platforms have opened up a form of peer to peer communication that until relatively recently, was reserved only for health care professionals. The empowered patient provides a unique opportunity for forward thinking life science companies. Patients are now
Details

It’s “high” time pharma executives embrace the promise of legal medical cannabis products. They hold much promise, therapeutically and economically. Medical cannabis has strong support from various advocacy groups. Failure to do so can lead to profits and industry jobs going up in smoke. Cannabis products or marijuana (recreational or medical) sales are legal only
Details

A revolution is afoot and the disrupting waves are influencing all sectors. The mystery is how all of this will play out on the national stage. A recent survey by Reuters shows that close to 70% of US citizens are in favor of the single-payer health care compared to the current system. Per Bernie Sanders,
Details

Just last week, the Trump administration delivered some surprising news. One of their flagship promises, to remove drug rebates related to Medicare and Medicaid, was being shelved. An array of reasons cited ranged from risk of higher insurance premiums to a potential upheaval of the entire system. However, there are still some who are convinced
Details

Gene and cell therapies Nothing is more exciting in medicine today than cell and gene therapy (CGT). Not that long ago, it was considered science fiction that a patient’s own cells could actually be modified to fight disease. This is now possible and destined to radically alter a disease course. Being such a new therapy,
Details

Now that the merger between CVS Health and Aetna is final, there is no better time to update our prior article which provided some interesting tidbits about the retail clinic business. There is no doubt that this marriage of two health care behemoths will generate a lot of upheaval in the public domain. Many stakeholders
Details

Welcome to the second post based on the Axios program Beyond 2020: Making Care Affordable featuring leading administration, legislative, and industry stakeholders. The goal of this program was to inspire thought on how best to manage the costs of prescription therapies. The first article in this series delved into the topic of the cost of new
Details

Scott Gottlieb, MD being interviewed by Axios’  Bob Herman. A jam-packed hour contemplating the future of health care, just another morning in DC. The Snowfish team heard leading administration, legislative, and industry stakeholders opine on the topic of Beyond 2020: Making Care Affordable, hosted by Axios.  On the docket were Scott Gottlieb, MD Former FDA
Details